Are the following areas under pre-clinical development, plus the GBM delivery system under re-design, what you are considering is the IP we are developing (in collab or otherwise)... that will underpin future patent applications by CHM?
- Undisclosed Next-Gen CAR NK study in blood and/or solid tumours (CHM 3301)
- CAR NK-cell study with CDH17 in solid tumours (CHM 2301)
- CAR NK-cell with CLTX (CHM 1301)
- CAR T-cell with CLTX in solid tumours (CHM 1101)
- CAR T-cell with CDH17 in solid tumours (CHM 2101)
If so, then some data readouts from any one of the above studies in the lab/s would be welcome. Pre-clinical data always seems to excite the masses, Bec!!! There is a lot of potential asset value there for CHM to trot out!
- Forums
- ASX - By Stock
- CHM
- Chimeric: Media Thread
Chimeric: Media Thread, page-821
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online